Format

Send to

Choose Destination
Nat Commun. 2015 Oct 27;6:8746. doi: 10.1038/ncomms9746.

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.

Author information

1
Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), 60 Biopolis Street, 02-01, Biopolis 138672, Singapore.
2
First Affiliated Hospital, Jinan University, Guangzhou 510632, China.
3
Cancer Research Institute, Jinan University, Guangzhou 510632, China.
4
The Kinghorn Cancer Center, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia.
5
Cancer Science Institute, National University of Singapore, Singapore 117599, Singapore.
6
School of Pharmacy, Jinan University, Guangzhou 510632, China.
7
Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense 5000, Denmark.
8
Department of Oncology, Odense University Hospital, Odense 5000, Denmark.
9
Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA.
10
Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore.
11
Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
12
Cancer and Stem Cell Biology, DUKE-NUS Graduate Medical School of Singapore, Singapore 169857, Singapore.

Abstract

Metastatic tumour recurrence due to failed treatments remains a major challenge of breast cancer clinical management. Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer (TNBC), where it acts to drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment. We show that IRAK1 overexpression confers TNBC growth advantage through NF-κB-related cytokine secretion and metastatic TNBC cells exhibit gain of IRAK1 dependency, resulting in high susceptibility to genetic and pharmacologic inhibition of IRAK1. Importantly, paclitaxel treatment induces strong IRAK1 phosphorylation, an increase in inflammatory cytokine expression, enrichment of cancer stem cells and acquired resistance to paclitaxel treatment. Pharmacologic inhibition of IRAK1 is able to reverse paclitaxel resistance by triggering massive apoptosis at least in part through inhibiting p38-MCL1 pro-survival pathway. Our study thus demonstrates IRAK1 as a promising therapeutic target for TNBC metastasis and paclitaxel resistance.

PMID:
26503059
PMCID:
PMC4640083
DOI:
10.1038/ncomms9746
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center